The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients (pts) with relapsed or refractory myelofibrosis (r/r-MF) and other advanced myeloid neoplasms: A phase (Ph) 1 study.
 
Justin Watts
Consulting or Advisory Role - Aptose Biosciences; Bristol-Myers Squibb; Daiichi Sankyo; Incyte; Rigel; SERVIER
Research Funding - Immune System Key
 
Alessandro Vannucchi
Honoraria - Novartis, BMS, Incyte, Blueprint, AbbVie, and AOP Orphans Pharmaceuticals
Consulting or Advisory Role - Novartis, AOP Orphans Pharmaceuticals, Incyte, AbbVie, Blueprint Medicines, GSK, and Roche
Other Relationship - lectures for Novartis, BMS, Incyte, Blueprint, AbbVie, and AOP Orphans Pharmaceuticals
 
Anthony Hunter
Honoraria - GSK, PharmaEssentia, Blueprint Medicines, Sobi (formerly CTI biopharma), and Incyte
Consulting or Advisory Role - Sierra Oncology
Research Funding - Incyte, Cogent Biosciences, Ascentage Pharma, Blueprint Medicines, Syntrix Biosystems, Novartis, and PharmaEssentia
 
Vikas Gupta
Stock and Other Ownership Interests - Syndax
Honoraria - Abbvie; Bristol-Myers Squibb/Celgene; CTI biophara; GlaxoSmithKline; Incyte; Novartis; Pfizer
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; CTI BioPharma Corp; GlaxoSmithKline; Incyte; Novartis
Research Funding - Abbvie (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patent on MPN24 a gene signature to predict outcome of Myelofibrosis (Inst)
 
Srinivas Tantravahi
Honoraria - from Karyopharm Therapeutics Inc, Novartis, GSK, MorphoSys, AbbVie, CTI BioPharma, Genentech, and Partnership for Health Analytic Research LLC
Consulting or Advisory Role - from Karyopharm Therapeutics Inc, Novartis, GSK, MorphoSys, AbbVie, CTI BioPharma, Genentech, and Partnership for Health Analytic Research LLC
Research Funding - Karyopharm Therapeutics
 
Junichiro Yuda
Research Funding - Abbvie; Amgen; AstraZeneca; Brighpath Bio; Bristol-Myers Squibb/Celgene; Celeid Therapeutics; Chugai Pharma; Daiichi Sankyo; Genmab; Incyte; Janssen; Mitsubishi Tanabe; MSD; Novartis; Sanofi; Sumitomo Pharma; Takeda
 
Alessandra Iurlo
Honoraria - AOP, BMS, GSK, Incyte, Novartis, and Pfizer
Consulting or Advisory Role - AOP, BMS, GSK, Incyte, Novartis, and Pfizer
 
Prithviraj Bose
Honoraria - Abbvie; Blueprint Medicines; BMS; Cogent Biosciences; CTI BioPharma Corp; GlaxoSmithKline; Incyte; Ionis Pharmaceuticals; Jubilant Therapeutics; Karyopharm Therapeutics; Morphic Therapeutic; MorphoSys; Novartis; Pharmaessentia
Consulting or Advisory Role - Ono Pharmaceutical; Sierra Oncology
Research Funding - Blueprint Medicines (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Cogent Biosciences (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Geron (Inst); Incyte (Inst); Ionis Pharmaceuticals (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Karyopharm Therapeutics (Inst); MorphoSys (Inst); Telios (Inst)
 
María Teresa Gómez Casares
No Relationships to Disclose
 
Brandon McMahon
Consulting or Advisory Role - GSK and PharmaEssentia
 
Francesca Palandri
Honoraria - Abbvie; Amgen; AOP Orphan Pharmaceuticals; Celgene; Celgene/Bristol-Myers Squibb; CTI; GlaxoSmithKline; Grifols; Karyopharm Therapeutics; MorphoSys; Novartis; Sierra Oncology; SOBI
Consulting or Advisory Role - Abbvie; Amgen; AOP Orphan Pharmaceuticals; Celgene; Celgene/Bristol-Myers Squibb; CTI; GlaxoSmithKline; Grifols; Karyopharm Therapeutics; MorphoSys; Novartis; Sierra Oncology; SOBI
 
Emma Searle
Honoraria - Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Johnson & Johnson/Janssen; Pfizer; Sanofi; Syndax
Travel, Accommodations, Expenses - Abbvie; BeiGene; Johnson & Johnson/Janssen; Menarini
 
Blanca Xicoy
No Relationships to Disclose
 
Andrew Srisuwananukorn
Consulting or Advisory Role - SOBI
 
Anna Halpern
Honoraria - Curio Science
Consulting or Advisory Role - Abbvie; Karyopharm Therapeutics; Notable labs
Research Funding - Bayer (Inst); Chordia Therapeutics (Inst); disc medicine (Inst); Gilead/Forty Seven (Inst); Incyte (Inst); Jazz Pharmaceuticals (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Pharmaessentia (Inst); Protagonist Therapeutics (Inst); Sumitomo Pharma Oncology (Inst)
 
Rosa Diaz
Consulting or Advisory Role - Novartis, Incyte
Speakers' Bureau - Astellas, BMS, Novartis
 
Jesus Hernandez
Honoraria - Amgen; GlaxoSmithKline; Pfizer
Consulting or Advisory Role - Amgen
Speakers' Bureau - Amgen (Inst); GlaxoSmithKline
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Akihiro Tomita
Honoraria - AstraZeneca, Chugai Pharmaceutical, AbbVie GK, Genmab, Kyowa Kirin, Eisai, Takeda Pharmaceutical, Astellas Pharma, Nippon Shinyaku, Janssen Pharmaceutical, Zenyaku Kogyo, Bristol-Myers Squibb, and SymBio Pharmaceutical
Research Funding - Chugai Pharmaceutical, Astellas Pharma, Eisai, Otsuka Pharmaceutical, Ono Pharmaceutical, Kyowa Kirin, Shionogi, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Takeda Pharmaceutical, Teijin, Nippon Shinyaku, Nihon Pharmaceutical, Pfizer Japan, Mochida P
 
Fred Zheng
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Pankit Vachhani
Consulting or Advisory Role - Abbvie; Amgen; Blueprint Medicines; Cogent Biosciences; Disc Medicine; Genentech/Roche; Geron; GlaxoSmithKline; Incyte; Kartos Therapeutics; Karyopharm Therapeutics; Merck; Merck; MorphoSys; Novartis; Novartis; Pfizer; SERVIER; SOBI; Stemline Therapeutics; Stemline Therapeutics; Takeda
Speakers' Bureau - Blueprint Medicines; Incyte
Research Funding - Abbvie (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); Blueprint Medicines (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Gilead/Forty Seven (Inst); Incyte (Inst); Kartos Therapeutics (Inst); Seagen (Inst); Takeda (Inst)
(OPTIONAL) Uncompensated Relationships - Board member: Alabama Cancer Congress